AbCellera Biologics : Corporate Overview

C O P Y R I G H T © A B C E L L E R A

May 2024

OVERVIEW

CORPORATE

DISCLAIMER

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward- looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

2

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

The most important drivers of

productivity in drug development are:

New insights into	Novel solutions to
the biology of disease	challenging problems

3

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

We have built an engine to generate first-in-class

and best-in-class antibody medicines.

Build a competitive advantage

Investments in technological capability can improve the productivity of drug development.

So you can solve hard problems

Long-term value creation comes from being able to repeatedly deliver first- in-classand best-in-classproducts.

4

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

After more than a decade, we are in the

final stages of completing the engine.

• 11+ years of investment in technology, teams,

and infrastructure

Manufacturing On Line

• More than $500M in platform investments, with integration from target to the clinic
• Final capital expenditures to complete clinical manufacturing capabilities will be concentrated in 2024
• Our capital allocation is shifting from building capabilities to using them

Late 2025

5

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

O U R P A R T N E R P O R T F O L I O

We built industry- leading capabilities through partnerships with the top-tier of biotech and pharma partners.

• Validated on 100+ therapeutic programs over the past 10+ years
• Leading capabilities on difficult targets and bispecifics
• A portfolio of passive royalty positions in therapeutic programs

90	human health: target antigen known	n = 78
%

18%	12%
neurology	immunology

51%	9%	5%	5%
oncology	other	ophthal-	infectious
		mology	disease

Partner-Initiated Programs

87 with Downstream Participation*

started are diversified across these therapeutic areas

*As of December 31, 2023

9%

animal health

n = 8

1%

human health: target antigen

TBD

n = 1

6

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

O U R P A R T N E R S

We are increasingly focused on strategic

partnerships.

We look for partnerships that bring new insights into novel biology or access to unique capabilities to create opportunities in therapeutic areas of shared interest.

AbbVie

Expanding relationships

with large pharma and large biotech

T-cell engager platform

deals in oncology and autoimmune conditions

Co-development

to access new targets and technology

Company creation

with top-tier venture capital groups

7

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

O U R F U T U R E

We are evolving

into an integrated

clinical biotech.

We have the platform and capital to build

1. proprietary pipeline of first-in-class and best-in-class medicines.

As of March 31, 2024

8

O U R E N G I N E . P L A T F O R M D E V E L O P M E N T

We are unlocking

high-value drug targets.

100	human health	n = 19
%

CORPORATE OVERVIEW

GPCR & Ion Channel Platform

• Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable using traditional methods for antibody discovery
• Many high-value targets for large unmet medical need in immunology, pain, endocrinology, fibrosis and more.

T-Cell Engager Platform

53%

undisclosed

GPCRs & ion channels

n = 10

42%

oncology & immunology

T-cell engagers

n = 8

infectious disease
5% pandemic response	1

COPYRIGHT © ABCELLERA

• Platform to create bispecific antibodies therapies with the potential for improved specificity and safety.
• Large, untapped market opportunity in solid tumors and autoimmunity.

AbCellera-Initiated Programs*

19 started across these therapeutic areas

*As of December 31, 2023

9

CORPORATE OVERVIEW

COPYRIGHT © ABCELLERA

O U R E N G I N E . P L A T F O R M D E V E L O P M E N T

We are using our T-cell engager platform as a source of internal programs and

a basis for strategic partnerships.

Our focus is to test in vivo and

to advance a subset of programs.

Our TCE platform is nearly complete.

In addition to having highly differentiated proprietary CD3s, we have also developed panels of antibodies that can be used to enhance T-cell activation, survival via signal-2 costimulation, and have demonstrated the ability to target MHC peptides.

10